Dodge & Cox Upped Anadarko Petroleum (APC) Holding By $644.49 Million; Last Week Abeona Therapeutics Inc. (ABEO) Analysts

January 13, 2018 - By Marie Mckinney

Dodge & Cox increased Anadarko Petroleum Corp (APC) stake by 40.94% reported in 2017Q3 SEC filing. Dodge & Cox acquired 13.43M shares as Anadarko Petroleum Corp (APC)’s stock declined 20.17%. The Dodge & Cox holds 46.22 million shares with $2.26 billion value, up from 32.79 million last quarter. Anadarko Petroleum Corp now has $32.27B valuation. The stock increased 0.82% or $0.48 during the last trading session, reaching $58.98. About 4.91M shares traded. Anadarko Petroleum Corporation (NYSE:APC) has risen 8.29% since January 13, 2017 and is uptrending. It has underperformed by 8.41% the S&P500.

Among 10 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics had 31 analyst reports since December 16, 2015 according to SRatingsIntel. The firm has “Buy” rating by Maxim Group given on Tuesday, August 29. Rodman & Renshaw reinitiated Abeona Therapeutics Inc. (NASDAQ:ABEO) rating on Wednesday, April 20. Rodman & Renshaw has “Buy” rating and $17 target. The firm has “Buy” rating by H.C. Wainwright given on Friday, September 8. Maxim Group maintained the stock with “Buy” rating in Wednesday, August 16 report. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) earned “Buy” rating by H.C. Wainwright on Thursday, January 4. The stock has “Buy” rating by FBR Capital on Thursday, May 25. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) has “Buy” rating given on Thursday, September 8 by Cantor Fitzgerald. The firm earned “Buy” rating on Friday, October 6 by Cantor Fitzgerald. The stock has “Buy” rating by Cantor Fitzgerald on Tuesday, July 18. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) has “Buy” rating given on Wednesday, November 22 by H.C. Wainwright. See Abeona Therapeutics Inc. (NASDAQ:ABEO) latest ratings:

04/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0 Maintain
22/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $30.0 Maintain
21/11/2017 Broker: Jefferies Rating: Buy New Target: $28.0 Maintain
08/11/2017 Broker: SunTrust Rating: Buy New Target: $26 Initiates Coverage On
02/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $23.0 Maintain
16/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $30.0 Maintain
12/10/2017 Broker: Cantor Fitzgerald Rating: Overweight Old Target: $21 New Target: $34 Maintain
10/10/2017 Broker: Citigroup Rating: Buy New Target: $32.0 Initiate
09/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $20.0 Maintain
06/10/2017 Broker: Jefferies Rating: Buy New Target: $27.0 Maintain

Investors sentiment increased to 0.84 in Q3 2017. Its up 0.02, from 0.82 in 2017Q2. It is positive, as 54 investors sold APC shares while 267 reduced holdings. 93 funds opened positions while 178 raised stakes. 468.24 million shares or 0.20% less from 469.17 million shares in 2017Q2 were reported. Etrade Mngmt Ltd Llc accumulated 0.03% or 17,040 shares. Sarasin And Prtn Limited Liability Partnership stated it has 0.99% of its portfolio in Anadarko Petroleum Corporation (NYSE:APC). Personal Advsr Corp has 349,809 shares. Renaissance Limited Liability holds 0.11% or 2.00M shares in its portfolio. Jane Street Limited Company holds 0% or 12,406 shares. 100 were accumulated by Exchange Mgmt. Duncker Streett And Inc owns 1,700 shares or 0.03% of their US portfolio. Putnam Investments Ltd stated it has 2.33 million shares or 0.26% of all its holdings. Boston Prtnrs invested 0.22% in Anadarko Petroleum Corporation (NYSE:APC). 86,815 are owned by Wolverine Asset Mgmt Ltd Liability. Fred Alger Mngmt stated it has 1,095 shares or 0% of all its holdings. Copeland Management Ltd Co reported 5,000 shares. Liberty Mutual Grp Asset holds 0.06% in Anadarko Petroleum Corporation (NYSE:APC) or 22,691 shares. Thrivent For Lutherans accumulated 699,482 shares. Beaconlight Capital Lc has invested 1.84% in Anadarko Petroleum Corporation (NYSE:APC).

Dodge & Cox decreased Fedex Corp (NYSE:FDX) stake by 105,347 shares to 11.27M valued at $2.54B in 2017Q3. It also reduced Mcdonald’s Corp (NYSE:MCD) stake by 2,600 shares and now owns 19,056 shares. Wal (NYSE:WMT) was reduced too.

Among 39 analysts covering Anadarko Petroleum Corporation (NYSE:APC), 32 have Buy rating, 2 Sell and 5 Hold. Therefore 82% are positive. Anadarko Petroleum Corporation had 119 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Sell” rating by Barclays Capital given on Thursday, December 21. The stock has “Buy” rating by RBC Capital Markets on Wednesday, December 20. On Wednesday, December 20 the stock rating was maintained by Jefferies with “Buy”. The company was maintained on Friday, September 1 by BMO Capital Markets. The stock of Anadarko Petroleum Corporation (NYSE:APC) earned “Outperform” rating by Credit Suisse on Wednesday, February 3. On Tuesday, July 25 the stock rating was maintained by Bank of America with “Buy”. The rating was upgraded by Guggenheim to “Buy” on Friday, November 11. On Thursday, December 21 the stock rating was reinitiated by PiperJaffray with “Overweight”. The rating was downgraded by Seaport Global to “Neutral” on Friday, December 9. As per Wednesday, February 3, the company rating was maintained by Barclays Capital.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $734.37 million. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

The stock decreased 0.95% or $0.15 during the last trading session, reaching $15.7. About 364,112 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 151.02% since January 13, 2017 and is uptrending. It has outperformed by 134.32% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>